Combination Therapy of Imiquimod 5%Cream and Cryotherapy vs Monotherapy for Common Warts:Randomized Comparative Trial.

NCT06973473 | Not Yet Recruiting

• 1 other identifier: Treatment of common warts
• Study Type: observational
• Target: 60
• Locations: 0 countries
• Sites: N/A

Brief Summary

To assess the clinical efficacy and safety of topical imiquimod 5% cream combined with cryotherapy versus either of theme alone for the treatment of common warts by clinical and dermoscopic assessments.

Conditions

Warts

Outcome Measures

Primary Outcomes (1)

• Complete clearance rate of common warts.

  Assessment of complete warts clearance rate at 12weeks to evaluate the efficacy of combination therapy ( imiquimod5%cream+cryotherapy ) compared to topical imiquimod5%cream alone or cryotherapy alone in patients with common wart.

  12 weeks

Eligibility Criteria

• Age: 18 Years - 60 Years
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)
• Sampling Method: Probability Sample

Study Population

\- study population age older than 18years

You may qualify if:

• Patients with common warts diagnosed clinically and by dermoscopy.
• Patients older than 18years old.

You may not qualify if:

• Pregnancy and lactation.
• Immunosuppression or being under any kind of treatment causing
• absolute or relative immunosuppression.
• Patients with chronic systemic diseases.
• All cases of bleeding tendency or using anticoagulants.
• Concurrent use of systemic or topical treatments of warts in the last 4 weeks.

Sponsors & Collaborators

• Assiut University: lead

MeSH Terms

Conditions

Warts

Condition Hierarchy (Ancestors)

Papillomavirus Infections; DNA Virus Infections; Virus Diseases; Infections; Skin Diseases, Viral; Tumor Virus Infections; Skin Diseases, Infectious; Skin Diseases; Skin and Connective Tissue Diseases

Central Study Contacts

Eman Fathy Ahmed Lecturer of Dermatology, Venereology and Andrology Faculty of

CONTACT

00201002258614; dr.emanfathy@aun.edu.eg

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: candidate

Study Record Dates

• First Submitted: April 29, 2025
• First Posted: May 15, 2025
• Study Start: July 1, 2025
• Primary Completion (Estimated): July 1, 2026
• Study Completion (Estimated): August 1, 2026
• Last Updated: May 15, 2025

Record last verified: 2025-05

Data Sharing

• IPD Sharing: Will not share